Beam Therapeutics (BEAM): Among the Stocks That Could 10x Over the Next 5 Years [Yahoo! Finance]
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine [Yahoo! Finance]
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
How The Investment Story For Beam Therapeutics (BEAM) Is Quietly Shifting With New Data And Funding [Yahoo! Finance]
Beam Therapeutics (BEAM) had its price target raised by Citigroup Inc. from $64.00 to $68.00. They now have a "buy" rating on the stock.